药物球囊在冠脉严重狭窄病变中的研究与应用

摘要/Abstract

摘要： 目的探讨与分析药物球囊在冠脉严重狭窄病变中的研究与应用价值。方法选择2019年1月—2022年4月在中国贵航集团三〇二医院诊治的153例冠脉严重狭窄病变患者作为研究对象,根据1∶1随机数表法把患者分为药物球囊组77例与药物支架组76例,药物支架组给予药物支架植入,药物球囊组给予药物球囊血管成形术,记录与随访两组患者的预后情况。结果治疗后1个月,药物球囊组治疗成功率为98.70%,与药物支架组的治疗成功率90.79%相比有提高,但组间差异无统计学意义（P>0.05）。治疗后1个月,两组左心室射血分数明显高于治疗前（P<0.05）,左室舒张末期内径明显低于治疗前（P<0.05）;治疗后1个月,药物球囊组左心室射血分数高于药物支架组（P<0.05）,左室舒张末期内径低于药物支架组（P<0.05）。治疗后1个月,两组6 min步行试验结果高于治疗前（P<0.05）,并且药物球囊组显著高于药物支架组（P<0.05）。治疗后6个月,药物球囊组心肌梗死、冠脉支架内再狭窄、血运重建、心源性死亡等心血管不良事件发生率,与药物支架组对比,差异无统计学意义（P>0.05）。结论药物球囊在冠脉严重狭窄病变中的应用能改善患者的心功能,也可提高患者的6 min步行试验距离,具有很好的安全性,特别是在分叉病变、小血管病变、支架内再狭窄及出血评分较高的患者中有较明显的优势。

关键词: 药物球囊, 冠脉严重狭窄病变, 心功能, 6 min步行试验, 心血管不良事件

Abstract: Objective To investigate and analyze the research and application values of drug balloon in severe coronary stenosis. Methods From January 2019 to April 2022, 153 cases of patients with severe coronary stenosis diagnosed and treated in our hospital were selected as the study subjects. Accorded to the 1∶1 random number table, the patients were divided into drug balloon group (77 cases) and drug stent group (76 cases). The drug stent group were treated with drug eluting stent therapy, and the drug balloon group were treated with drug balloon. The prognosis of the patients in the two groups were recorded and followed up. Results 1 month after treatment, the treatment success rate of drug balloon groupwas 98.70%, compared with 90.79% in the drug stent group, there was no statistical significance (P>0.05). 1 month after treatment, LVEF was significantly higher than before treatment (P<0.05), LV end-diastolic internal diameter was significantly lower than before in both groups (P<0.05), 1 month after treatment, LVEF in the drug balloon group was higher than that in the drug stent group (P<0.05), and LV end-diastolic internal diameter was lower than the stent group (P<0.05).The 6-min walk test results at 1 month after treatment were higher than before treatment (P<0.05), and the drug balloon group was significantly higher than the drug stents (P<0.05).The incidence rates of adverse cardiovascular events such as myocardial infarction, coronary stent restenosis, revascularization, and cardiac death at 6 months after treatment in the drug balloon group, which compared to the drug stent group were not significantly difference (P>0.05). Conclusion The application of drug balloon in severe coronary stenosis can improve the cardiac function of patients, increase the 6-minute walking test distance of patients, it also has good safety, especially in patients with bifurcation disease, small vessel disease, in stent restenosis and high bleeding score.

Key words: drug balloon, severe coronary stenosis, cardiac function, 6 min walking test, cardiovascular adverse events

中图分类号:

张开萍, 黄平, 梁洪涛, 柴方云, 李攀. 药物球囊在冠脉严重狭窄病变中的研究与应用[J]. 中华养生保健, 2023, 41(13): 12-15.

ZHANG Kai-ping, HUANG Ping, LIANG Hong-tao, CHAI Fang-yun, LI Pan. Study and Application of Drug Balloon in Severe Coronary Stenosis[J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(13): 12-15.

参考文献

[1] 蔡金赞,陈凯伦,贾海波,等.普通球囊、药物涂层球囊及药物洗脱支架治疗冠状动脉支架内再狭窄的长期疗效Meta分析[J].中国循环杂志,2018,33(9):873-878.
[2] LIN F, WANG H, DING W, et al.Atherectomy plus drug-coated balloon versus drug-coated balloon only for treatment of femoropopliteal artery lesions: A systematic review and meta-analysis[J]. Vascular,2021,29(6):883-896.
[3] LIU C, WOLFERS M, AWAN B Z, et al.Drug-Coated Balloon Versus Plain Balloon Angioplasty for Hemodialysis Dysfunction: A Meta-Analysis of Randomized Controlled Trials[J]. J Am Heart Assoc,2021,10(23):e022060.
[4] 岳沛林,李杨.冠状动脉旁路移植联合右侧颈动脉内膜剥脱及颈动脉支架置入一站式复合手术1例[J].中国循证心血管医学杂志,2022,14(2):237-238.
[5] 陆洪涛,王联发,童全秀,等.药物涂层球囊治疗对冠状动脉分叉病变患者的疗效[J].心血管康复医学杂志,2022,31(4):446-450.
[6] WU X, LI L, HE L.Drug-Coated Balloon versus Drug-Eluting Stent in Patients with Small-Vessel Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials[J]. Cardiol Res Pract,2021,8(16):1647635.
[7] YE W, ZHANG X, DAI X, et al.Reewarm™ PTX drug-coated balloon in the treatment of femoropopliteal artery disease: A multi-center, randomized controlled trial in China[J]. Int J Cardiol,2021,326:164-169.
[8] 姚仙,刘聪.参芪瓜蒌薤白半夏汤在药物球囊干预不稳定型心绞痛单支罪犯血管中的应用[J].辽宁中医药大学学报,2022,24(2):127-130.
[9] 李晓阳,陆炜,程国兵,等.药物涂层球囊治疗右锁骨下动脉盗血综合征的有效性和安全性[J].介入放射学杂志,2022,31(8):761-764.
[10] 黄捷,王宁宁,于文武,等.药物涂层球囊预扩联合支架置入治疗椎动脉起始部狭窄的临床疗效分析[J].实用医院临床杂志,2022,19(5):78-81.
[11] 李占鲁,黄翯.紫杉醇涂层球囊的应用现状和不足以及新一代药物涂层球囊的研究进展[J].中国介入心脏病学杂志,2022,30(4):299-302.
[12] SUN G, LIU J, JIA S, et al.Comparison of drug-coated balloon angioplasty versus uncoated balloon angioplasty in treatment of total occlusions with severe femoropopliteal lesions: An additional analysis from the AcoArt I study[J]. Vascular,2021,29(3):340-349.
[13] VAN WIJCK I P, HOLEWIJN S, VAN WALRAVEN L A, et al. Drug-coated balloon angioplasty for the treatment of edge stenosis after self-expanding covered stent placement for superficial femoral artery occlusive disease[J]. Vascular,2021,29(1):108-115.
[14] 蔺松若,唐文贤,姜伟庆,等.药物涂层球囊治疗老年下肢动脉硬化闭塞症经皮穿刺血管腔内成型术术后支架内再狭窄的疗效及安全性[J].海南医学,2022,33(11):1375-1378.
[15] 杨新越,郑悠阳,林立,等.原位冠状动脉弥漫性病变药物涂层球囊植入术后晚期管腔扩大的影响因素[J].山东医药,2022,62(7):50-52.
[16] AHMED S W, HUSSAIN B, AHMED B, et al.Drug-Eluting Balloon for Management of Coronary In-Stent Restenosis in a South Asian Population: Experience From a Tertiary-Care Hospital in Pakistan[J]. J Invasive Cardiol,2021,33(2):E127-E134.
[17] BENJAMIN B K, LU W, HAN Z, et al.Drug-Coated Balloon-Only Angioplasty Outcomes in Diabetic and Nondiabetic Patients with De Novo Small Coronary Vessels Disease[J]. J Interv Cardiol,2021,9(15):2632343-2632349.
[18] CAO S, HE T, XIE J, et al.Drug-coated balloon angioplasty versus balloon angioplasty for treating patients with in-stent restenosis in the femoropopliteal artery: A meta-analysis[J]. Medicine (Baltimore), 2021,100(16):e25599.
[19] ELLIOTT S P, COUTINHO K, ROBERTSON K J, et al.One-Year Results for the ROBUST III Randomized Controlled Trial Evaluating the Optilume(®) Drug-Coated Balloon for Anterior Urethral Strictures[J]. J Urol,2022,207(4):866-875.
[20] JIA X, ZHUANG B, WANG F, et al.Drug-Coated Balloon Angioplasty Compared With Uncoated Balloons in the Treatment of Infrapopliteal Artery Lesions (AcoArt II-BTK)[J]. J Endovasc Ther,2021,28(2):215-221.